Lyell Immunopharma Stock In The News

LYEL Stock  USD 0.58  0.05  9.43%   
Our overall analysis of Lyell Immunopharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Lyell Immunopharma. The specific impact of Lyell Immunopharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Lyell Immunopharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Lyell Immunopharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Lyell Immunopharma Backtesting and Lyell Immunopharma Hype Analysis.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

Lyell Immunopharma Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
https://www.globenewswire.com/news-release/2025/03/11/3040985/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024.html
 Bullish
Macroaxis News: globenewswire.com
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
https://www.globenewswire.com/news-release/2023/11/09/2777799/0/en/Lyell-Immunopharma-Receives-FDA-Orphan-Drug-Designation-for-LYL845-for-the-Treatment-of-Melanoma.html
 Neutral
Macroaxis News: globenewswire.com
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
https://www.globenewswire.com/news-release/2023/11/07/2775581/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Third-Quarter-2023.html
 Bullish
Macroaxis News: globenewswire.com
Lyell Immunopharma Presentations at SITC...
https://www.globenewswire.com/news-release/2023/10/31/2770260/0/en/Lyell-Immunopharma-Presentations-at-SITC-Highlight-New-Nonclinical-Data-on-Product-Candidates-and-Innovative-Technology-to-Shorten-TIL-Manufacturing.html
 Neutral
Macroaxis News: globenewswire.com
Lyell Immunopharma Announces the Accepta...
https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
https://www.globenewswire.com/news-release/2023/09/11/2740721/0/en/Cellares-and-Lyell-to-Evaluate-Automated-Manufacturing-of-Lyell-s-CAR-T-Cell-Therapy-on-Cellares-Cell-Shuttle-Platform.html
 Neutral
Macroaxis News: globenewswire.com
Lyell Immunopharma to Participate in Upcoming Investor Conferences
https://www.globenewswire.com/news-release/2023/08/31/2735682/0/en/Lyell-Immunopharma-to-Participate-in-Upcoming-Investor-Conferences.html
 Neutral
Macroaxis News: globenewswire.com
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
https://www.globenewswire.com/news-release/2023/08/08/2721110/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-Second-Quarter-2023.html
 Bullish
Macroaxis News: globenewswire.com
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
https://www.globenewswire.com/news-release/2023/07/05/2699908/0/en/Lyell-Immunopharma-Appoints-Matthew-Lang-as-Chief-Business-Officer.html
 Bullish
Macroaxis News: globenewswire.com
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
https://www.globenewswire.com/news-release/2023/06/07/2684237/0/en/Lyell-Immunopharma-to-Participate-in-the-Goldman-Sachs-Global-Healthcare-Conference.html
 Neutral

Lyell Immunopharma Past News Timeline

From Mar 22 to Dec 21Use up and down arrows to move selectionTo Mar 22Use up and down arrows to move upper selectionFrom Dec 21Use up and down arrows to move lower selectionUse TAB select grip buttons or up and down arrows to change selection100%
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Lyell and other traded companies coverage with news coverage. We help investors stay connected with Lyell headlines for the 22nd of March to make an informed investment decision based on correlating the impacts of news items on Lyell Stock performance. Please note that trading solely based on the Lyell Immunopharma hype is not for everyone as timely availability and quick action are needed to avoid losses.
Lyell Immunopharma's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Lyell Immunopharma investors visualize upcoming and past events in order to time the market based on Lyell Immunopharma noise-free hype analysis.
Lyell Immunopharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Lyell earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Lyell Immunopharma that are available to investors today. That information is available publicly through Lyell media outlets and privately through word of mouth or via Lyell internal channels. However, regardless of the origin, that massive amount of Lyell data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lyell Immunopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lyell Immunopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lyell Immunopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lyell Immunopharma alpha.

Lyell Largest EPS Surprises

Earnings surprises can significantly impact Lyell Immunopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-08
2024-06-30-0.205-0.180.02512 
2024-11-08
2024-09-30-0.2-0.170.0315 
2024-02-28
2023-12-31-0.23-0.20.0313 
2025-03-12
2024-12-31-0.13-0.1721-0.042132 
2023-05-04
2023-03-31-0.28-0.230.0517 
2024-05-07
2024-03-31-0.21-0.150.0628 
View All Earnings Estimates

Lyell Immunopharma Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Lyell Immunopharma Stock. Current markets are strongly bearish. About 79% of major world exchanges and indexes are down. See today's market update for more information.
news
21st of March 2025
Lynn Seely Buys 175,000 Shares of Lyell Immunopharma, Inc. Stock
at thelincolnianonline.com 
Google News at Macroaxis
18th of March 2025
Lyell Immunopharma stock hits 52-week low at 0.51 - Investing.com India
at news.google.com 
news
14th of March 2025
Acquisition by Seely Lynn of 175000 shares of Lyell Immunopharma at 0.6068 subject to Rule...
at thelincolnianonline.com 
Gurufocus Stories at Macroaxis
11th of March 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarte...
at gurufocus.com 
Google News at Macroaxis
5th of March 2025
BlackRock, Inc. Reduces Stake in Lyell Immunopharma Inc - GuruFocus.com
at news.google.com 
Yahoo News
31st of January 2025
Lyell Immunopharma, Inc. has caught the attention of institutional investors who hold a si...
at finance.yahoo.com 
zacks News
22nd of January 2025
Lyell Immunopharma Upgraded to Strong Buy Heres Why
at zacks.com 
zacks News
30th of December 2024
After Plunging -31.22 percent in 4 Weeks, Heres Why the Trend Might Reverse for Lyell Immu...
at zacks.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lyell Immunopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lyell Immunopharma's short interest history, or implied volatility extrapolated from Lyell Immunopharma options trading.
When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:
Check out Lyell Immunopharma Backtesting and Lyell Immunopharma Hype Analysis.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.42)
Quarterly Revenue Growth
(0.15)
Return On Assets
(0.22)
Return On Equity
(0.66)
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

RVMD
Revolution Medicines
38.11  -0.38  -0.99 
SANA
Sana Biotechnology
2.31  0.05  2.21 
GBIO
Generation Bio
0.50  -0.02  -3.85 
MLYS
Mineralys Therapeutics,
16.87  0.14  0.84 
News Freq…Investor S…